Dive Brief:
- Zimmer Biomet said Tuesday it has restructured its leadership team, promoting three people and parting ways with a fourth executive.
- The orthopedic company framed the changes as streamlining its Americas and global business group organizations and accelerating its commercial transformation.
- Stifel analysts welcomed the changes, telling investors in a note that they provide a “clearer division of labor” and support the ongoing overhaul of Zimmer’s sales force.
Dive Insight:
Zimmer is transforming its 2,500-person U.S. sales force by replacing independent contractors with fully dedicated specialists. While the process will take until the end of next year, Zimmer provided an upbeat progress update last month, telling investors that it was seeing less customer disruption and sales force turnover than initially expected.
This week’s changes affect the upper echelons of Zimmer’s organization. Effective Oct. 1, Zimmer will promote Gary Campbell to president, Americas, and Brian Hatcher to president, recon, S.E.T., CMFT, neuro and biosurgery. Zimmer is also promoting Bradley Kessler to president, Americas, robotics, technology and data. Campbell, Hatcher and Kessler will report directly to Zimmer CEO Ivan Tornos.
Kevin Thornal, group president, global businesses and the Americas, will leave Zimmer at the end of this month. Zimmer appointed Thornal, the former CEO of Nevro, to the newly created role last year. Thornal will receive severance payments, including a lump sum equal to his annual base salary and target bonus.
The changes highlight Zimmer’s ongoing push for more managerial and commercial efficiencies, Stifel analysts said. The medtech company’s “growth acceleration-focused transformation remains very much directionally on track,” the analysts added.
The three promoted executives “are seasoned operators and proven Zimmer Biomet leaders with deep experience in the businesses and markets they will now lead,” Tornos said in a statement. Promoting the executives reinforced Tornos’ “strong confidence” in Zimmer’s 2026 outlook and future growth potential.
Zimmer reiterated its full-year 2026 financial outlook in conjunction with the restructuring. The decision to reiterate guidance two months into the third quarter suggests that the company is on track to meet its full-year goals, the analysts said.
The reiterated outlook is “particularly encouraging” in light of “somewhat unsettling” comments from Stryker about joint replacement volumes, the analysts said. Stryker CFO Preston Wells commented on volumes at a Wells Fargo event on Tuesday, telling attendees that “we expected there to be a stronger summer in the U.S.”
